The estimated market size of the two ANDAs put together is nearly $200 million
Zydus Healthcare, a subsidiary of Cadila Healthcare has acquired two abbreviated new drug applications (ANDAs) from Teva Pharmaceutical in the US for an undisclosed sum.
“Zydus has strengthened its US portfolio with the acquisition of two ANDAs from Teva that are being divested by Teva as a pre-condition to its acquisition of Allergan’s generic business,” Cadila Healthcare said in a BSE filing.
It further said: “The acquisition of these ANDAs is contingent on the closing of the Teva-Allergan Genercis transaction and approval by the US Federal Trade Commission. Financial details of the transaction are undisclosed.”
The company said these ANDAs have been acquired by its 100 per cent subsidiary, Zydus Worldwide DMCC and will be financed through the group’s internal accruals.
Giving details about the ANDAs, the company said that the acquired portfolio comprises an ANDA which is already commercialised and one pipeline ANDA which is a transdermal patch. The estimated market size of the two ANDAs put together is nearly $200 million.